Cost-Effectiveness of Ivonescimab Plus Chemotherapy Versus Chemotherapy Alone in EGFR-Mutant Non-Small Cell Lung Cancer After EGFR-TKI Failure: A Partitioned Survival Analysis of the HARMONi-A Randomized Clinical Trial
Based on a partitioned survival analysis of the HARMONi-A trial, the addition of ivonescimab to chemotherapy for EGFR-mutant non-small cell lung cancer patients who have failed EGFR-TKI therapy is not cost-effective under current Chinese drug prices, as the incremental cost-effectiveness ratio significantly exceeds the willingness-to-pay threshold due to high acquisition costs and modest survival gains.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Lung cancer remains the most common cause of cancer death worldwide, and for many patients, the disease begins with a specific genetic change known as an EGFR mutation. For years, doctors have treated these patients with targeted pills that block this mutation, often with great success. However, the cancer almost always learns to resist these drugs over time, leaving patients with very few options once the pills stop working. In this difficult second-line setting, a new type of medicine called a bispecific antibody has emerged. This drug, named ivonescimab, works by attacking the cancer on two fronts at once: it blocks a protein that helps tumors hide from the immune system and another that helps tumors build new blood vessels. While early trials showed this approach could extend the time before the cancer grows again, a crucial question remained unanswered for health systems in China: does the extra time gained justify the high price of the new drug?
To answer this, researchers built a detailed computer model to simulate the lives of patients with this specific type of lung cancer. They used data from a major clinical trial called HARMONi-A, which compared patients receiving standard chemotherapy alone against those receiving the same chemotherapy combined with ivonescimab. The model tracked patients over a ten-year period, dividing their time into three states: being alive without the cancer growing, living with the cancer growing, and death. By feeding the trial's survival numbers into this model, the team could estimate how many extra months of healthy life the new drug provided and how much it would cost the healthcare system. They calculated the value of this treatment by weighing the additional time patients lived against the financial burden, using a standard benchmark for what a country is willing to pay for a year of healthy life.
The results painted a clear picture of a treatment that works clinically but struggles economically. Patients receiving the combination of ivonescimab and chemotherapy lived longer than those on chemotherapy alone, gaining an average of about two to three months of overall survival. In terms of quality-adjusted life years—a measure that accounts for both how long patients live and how well they feel during that time—the new treatment added roughly 0.16 extra years. However, this modest gain came at a steep price. The combination therapy cost nearly nineteen thousand dollars more per patient than chemotherapy alone. When the researchers calculated the cost for each additional year of healthy life gained, the number was nearly one hundred and twenty thousand dollars. This figure is almost three times higher than the threshold that Chinese health experts consider a good value for money.
The study explored whether changing certain assumptions could make the treatment look more affordable. They tested scenarios where the drug cost less, where patients lived longer than the trial suggested, or where the value of health was calculated differently. Even when they reduced the price of the new drug by twenty percent, the cost per year of healthy life remained far too high to be considered a standard value. The analysis showed that for the treatment to become a financially sound choice under current standards, the price of ivonescimab would need to drop by nearly eighty percent. Without such a dramatic price reduction, the extra survival benefit, while real and meaningful to the individual patient, does not represent a high-value use of limited healthcare resources in China.
Ultimately, the research suggests that while this new drug offers a genuine lifeline for patients who have run out of other options, the economic reality is stark. The absolute gain in survival time is small because the patients are already heavily treated and the disease is advanced, while the cost of the drug remains very high. The study concludes that at current prices, adding this innovative antibody to standard chemotherapy is not a cost-effective strategy for the Chinese healthcare system. This finding does not diminish the clinical success of the drug, which significantly delays cancer progression, but it highlights the difficult balance between medical innovation and economic sustainability when treating patients with limited life expectancy.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.